Navigation Links
First Human Study to Show 'Sun Chlorella A' Supports Heart Health
Date:3/30/2009

RICHMOND, Va., March 30 /PRNewswire/ -- A new study, published in the Journal of Medicinal Food, showed that consumption of as little as 8 grams (1/3 ounce) of "Sun Chlorella A" daily resulted in noticeable reductions in body fat percentage, serum total cholesterol, and fasting blood glucose levels.

For a 12-week period, 34 participants ingested four grams of "Sun Chlorella A" tablets each morning and evening. Seventeen subjects were healthy; the other 17 were at high risk for developing lifestyle-related illnesses.

Both groups had a decrease in body fat percentage and total serum cholesterol. However, the high-risk group also experienced lowered blood glucose, possibly due to improved insulin sensitivity induced by adding Chlorella to the daily diet.

Heart disease and stroke are the number one and three causes of death for both men and women in the U.S. Risk factors include elevated serum cholesterol, high blood pressure, a sedentary lifestyle, unhealthy diet, smoking, obesity, and hyperglycemia.

According to Mark Drucker, M.D., "Heart health is important to everyone. Remember, our hearts must be nourished to stay healthy. With protein, minerals, vitamins and fiber, Sun Chlorella is what I take, and what I recommend to all my patients."

Chlorella is a single-cell, fresh water green alga. Past research has shown that Chlorella is effective for immune activation, growth promotion, and detoxification of heavy metals and pesticides. However, unlike this recent study, most of the prior research used laboratory animals.

Dr. Randall E. Merchant earned his Doctoral and Master of Sciences degrees from the University of North Dakota. Dr. Merchant is a Professor of Anatomy and Neurosurgery at Virginia Commonwealth University, and has conducted several clinical investigations on the role of nutrition on overcoming the effects of certain chronic illnesses.

References

Toru Mizoguchi, Isao Takehara, Tohru Masuzawa, Toshiro Saito, and Yo Naoki, "Nutrigenomic Studies of Effects of Chlorella on Subjects with High-Risk Factors for Lifestyle-Related Diseases", JOURNAL OF MEDICINAL FOOD, J Med Food 11 (3) 2008, 395-404

Janet Poveromo, Aiming for the Heart to Target Cardiovascular Health Specifically Ingredient Companies are Broadening their Scope of What's Beneficial, niemagazine.com, October 2008


'/>"/>
SOURCE Randall E. Merchant, Ph.D.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):